observation of a clear-cut , supranormal decrease in blood pressure during the intravenous infusion of the angiotensin ii antagonist , saralasin , has provided a far more reliable indication of the presence of an angiotensinogenic component in the hypertension .
C0003009
angiotensin ii
C0036193
saralasin